NovoCure Ltd Q2 2026 Earnings
As seen on the 24/7 Wall St. homepage on July 23, 2026.
Q2 2026
EPS
$-0.13
est $-0.33
+60.9%
Revenue
$184M
est $173M
+6.3%
NovoCure crushed expectations with active patients surging 18% to 5,128 and swinging to positive Adjusted EBITDA, sending the cancer therapy company to a $0.13 loss per share that beat estimates by 61%. The company lifted full-year revenue guidance to $710 million to $725 million on the strength of Optune Lua and Optune Pax, which together pulled in $7 million this quarter.
Mentioned: NVCR